Positron-Emission Tomography(PET), Solid Tumor
Conditions
Brief summary
The purpose of this study is to evaluate the safety of \[68Ga\]Ga-NOTA-SNA002 and investigate the uptake of \[68Ga\]Ga-NOTA-SNA002 in patients with solid tumors.
Detailed description
After being informed about the study and potential risks, all patients giving written informed consent will be evaluated to determine eligibility for study entry. Patients will receive an injection of \[68Ga\]Ga-NOTA-SNA002 (1.0-5.0mCi) in Day1 and will undergo PET/CT scanning to determine uptake of \[68Ga\]Ga-NOTA-SNA002 in tumor lesions and reference tissues.
Interventions
BIOLOGICAL[68Ga]Ga-NOTA-SNA002
\[68Ga\]Ga-NOTA-SNA002（PD-L1 PET Tracer）for Positron Emission Tomography
Sponsors
The First Affiliated Hospital of Soochow University
SmartNuclide Biopharma
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
DIAGNOSTIC
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
No
Inclusion criteria
1. Age 18-75 years (including boundary values); 2. Have behavioral ability, and voluntarily participate in this clinical study, and sign the informed consent form (ICF); 3. Performance status (ECOG) score 0-2 points (see Appendix 1 for details); 4. Basal heart rate 60-100 beats/min (including boundary values); 5. Blood pressure measurement \< hypertension grade 1 level (including a history of hypertension, systolic blood pressure \< 140 and diastolic blood pressure \< 90 mmHg by exercise or drug treatment); 6. Patients with confirmed solid tumors; 7. Patients who must have at least one image-measurable lesion according to the evaluation criteria for solid tumors (RECISTv1.1); 8. Imaging results show that at least one tumor lesion can be needle biopsy or surgical treatment to obtain specimens (enhanced CT, enhanced MRI or 18F-FluroDeoxyGlucose(FDG) PET/CT results are acceptable); 9. Patients obtained with immunohistochemical PD-L1 expression results within the previous month.
Exclusion criteria
1. Those who are unable to follow this clinical trial protocol well enough to make visits, or undergo relevant examinations, or treatment; 2. Those who have extremely poor nutritional status and cannot tolerate the trial; 3. Known or suspected evidence of active autoimmune disease; 4. Patients taking high doses of hormones, such as more than 20mg of hydrocortisone or 5mg of prednisone in the morning and more than 10mg of hydrocortisone or 2.5mg of prednisone at night； 5. Those with known severe allergy to SNA002, similar drugs or excipients； 6. Patients with brain metastases； 7. Serum virology tests: positive results for any of hepatitis B virus surface antigen, hepatitis C virus antibodies, syphilis-specific antibodies or those who cannot be determined to be negative for human immunodeficiency virus antibodies； 8. Women who are pregnant or breastfeeding. 9. Those who, in the opinion of the investigator, are not suitable to participate in this clinical study.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Description of biodistribution patterns of [68Ga]Ga-NOTA-SNA002 on PET | 1 month | Description of biodistribution patterns of \[68Ga\]Ga-NOTA-SNA002 on PET. |
| Incidence of adverse events | Time of infusion of [68Ga]Ga-NOTA-SNA002 (Day 1) through Visit（Day 6） | The incident and severity of adverse events per CTCAE V5.0 criteria will be recorded following dose of \[68Ga\]Ga-NOTA-SNA002. |
| Changes of vital signs in participants compared with baseline results. | Baseline and 6 hours after infusion of [68Ga]Ga-NOTA-SNA002 (Day 1) and 2 hours after tumor biopsy(Day 2) | Number of participants in CTCAE 5.0 Stage 1 or higher with vital signs after administration |
| Changes in laboratory values compared with baseline results. | Baseline and Visit（Day 6） | Number of participants in CTCAE 5.0 Stage 1 or higher with laboratory examination(e.g. WBC, RBC, HB and other laboratory tests) after administration. |
| Immunogenicity Analysis of [68Ga]Ga-NOTA-SNA002 | 1 month | By analyzing anti-SNA002 anti-drug antibody positive rate. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Standard Uptake Value(peak) in tumors | 12 months | SUVpeak quantitative analysis in tumors |
| Standard Uptake Value(mean) in tumors | 12 months | SUVmean quantitative analysis in tumors |
| Correlation of [68Ga]Ga-NOTA-SNA002 uptake in biopsied tumors with PD-L1 measurement by immunohistochemistry (IHC) | 12 months | Analyze \[68Ga\]Ga-NOTA-SNA002 uptake in biopsied tumors as determined by SUV-based quantitative measures (SUVmax, SUVpeak, SUVmean) with PD-L1 measurement determined by IHC from biopsy samples. |
| Standard Uptake Value(max) in tumors | 12 months | SUVmax quantitative analysis in tumors |
Countries
China
Contacts
Primary ContactHua Zhang
Backup ContactYan Wang, Ph.D
Outcome results
None listed